Latest Recruitment News

Arovella Therapeutics has secured a crucial regulatory nod from the U.S. FDA, allowing its lead CAR-iNKT cell therapy, ALA-101, to enter first-in-human clinical trials targeting blood cancers.

Nova Eye Medical has reported a record US$6.1 million in global sales for the December 2025 quarter, marking a 38% year-on-year increase and strong momentum across key markets. The company’s innovative iTrack™ technology continues to drive growth, supported by expanded manufacturing capacity and advancing clinical programs.

Cleo Diagnostics has broadened its U.S. market opportunity to around 2 million women annually and is on track to complete its pivotal clinical trial early this year, supported by a $5 million capital raise and regulatory progress.

Cyclopharm has launched a pioneering clinical study combining its Technegas imaging with AI analysis to explore a novel treatment for severe COPD, potentially expanding care options for millions.

Aurelia Metals announces Managing Director Bryan Quinn will resign by July 2026, with a leadership search underway amid key project developments.

Emyria Limited has reported strong quarterly revenue growth driven by the expansion of its Empax clinic network across multiple Australian states, supported by a recent $8 million institutional placement to fund its national rollout and workforce expansion.

Boss Energy delivered a record uranium production quarter at its Honeymoon project, lowering cost guidance and initiating a new feasibility study to reshape its mining strategy.

Minerals 260 Limited has significantly expanded its Bullabulling Gold Project resource to 4.5 million ounces, nearly doubling its previous estimate, while advancing key development milestones ahead of a mid-2026 Pre-Feasibility Study completion.

LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.

EMVision Medical Devices reports strong clinical trial progress for its portable brain scanners, backed by solid cash reserves and milestone grant funding.

Austral Resources Australia Ltd has emerged strongly from a 26-month ASX suspension, delivering robust copper production and sales that beat expectations in the December 2025 quarter. The company’s strategic acquisitions and exploration efforts position it for growth in 2026.